-
Type 1 Diabetes Market Size to Reach USD 9.6 billion by 2035 | Epidemiology, Treatment, Trends & Rising Incidence
17 Jun 2025 14:29 GMT
… hybrid systems demonstrates their clear benefits to patients.
Digital health is … in the market.
MannKind Corporation
Eli Lilly and Company
Sanofi
AstraZeneca
Oramed Pharmaceuticals
ImCyse …
-
VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders
17 Jun 2025 15:17 GMT
… Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders … transaction, or other relief and benefits. We would handle the action …
-
Futures Slide, Oil Rises As Mideast Tensions Build
17 Jun 2025 12:39 GMT
US stock futures and global markets are broadly lower on escalation/contagion worries in the Middle East after Trump called for the evacuation of Tehran and cut short his G-7 visit, and yet, as BBG notes, traders don’t seem too perturbed, with futures …
-
As DEI Comes Under Attack, Inkwell Beach Stands Resilient Against the Storm in Year 5 at Cannes Lions: ‘To Be Able to Show Up Is a Win in Itself…
17 Jun 2025 08:25 GMT
… -chip brands as Accenture, Amgen, Eli Lilly and Co., Getty Images, Havas, Interpublic Group … buyers and planners about the benefit of this media. Because what …
-
Innovent completes first patient dosing in seventh phase 3 trial (GLORY─OSA) of mazdutide in China with moderate─to─severe OSA & obesity
17 Jun 2025 06:27 GMT
… certain patients experience transformative benefits from PAP. Challenges exist … cardiovascular and metabolic benefits. The 9 mg … exclusive license agreement with Eli Lilly and Company (Lilly) for the … It has also shown benefits in reducing waist circumference …
-
Innovent Announces Completion Of First Participant Dosed In The Seventh Phase 3 Clinical Trial (GLORY-OSA) Of Mazdutide In China
16 Jun 2025 04:03 GMT
… certain patients experience transformative benefits from PAP. Challenges exist … cardiovascular and metabolic benefits. The 9 mg … exclusive license agreement with Eli Lilly and Company (Lilly) for the … It has also shown benefits in reducing waist circumference …
-
Experimental obesity drug shows promise
15 Jun 2025 21:50 GMT
An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the obesity market.
The drug, called eloralintide, …
-
VIDEO: Camizestrant combination reduces risk for breast cancer progression, mortality
15 Jun 2025 15:12 GMT
June 15, 2025
5 min watch
CHICAGO — In this video, Erica L. Mayer, MD, MPH, discusses the SERENA-6 study, which assessed the efficacy of switching to camizestrant plus a CDK 4/6 inhibitor vs. continuing standard treatment among patients with advanced …
-
Lilly’s experimental obesity drug shows promise in early study
14 Jun 2025 21:42 GMT
An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the obesity market.
The drug, called eloralintide, …
-
VIDEO: Abemaciclib dose-escalation strategy promising for some patients with breast cancer
14 Jun 2025 14:18 GMT
June 14, 2025
4 min watch
CHICAGO — In this video, Erica L. Mayer, MD, MPH, director of breast cancer clinical research at Dana-Farber Cancer Institute, discusses results of the TRADE study, which she presented at ASCO Annual Meeting. The phase 2 trial …
About
© 1995-2025